^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

FT576

i
Other names: FT576, iPSC-derived, multi-antigen targeted CAR-BCMA NK cell therapy
Associations
Trials
Company:
Fate Therap
Drug class:
CD38 inhibitor, BCMA inhibitor
Associations
Trials
3ms
FT576 in Subjects With Multiple Myeloma (clinicaltrials.gov)
P1, N=31, Active, not recruiting, Fate Therapeutics | Recruiting --> Active, not recruiting | N=168 --> 31
Enrollment closed • Enrollment change • Combination therapy
|
cyclophosphamide • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT576
2years
Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma (ASH 2022)
Outpatient conditioning chemotherapy consists of 3 consecutive days of fludarabine and cyclophosphamide administered prior to the first dose of FT576. Administration of a single dose of FT576 at 100 or 300 million cells/dose alone or in combination with daratumumab is safe and well tolerated thus far without CRS, neurotoxicity, or GvHD. Interim clinical data, including safety and tolerability and initial anti-tumor activity, from the ongoing Phase I dose-escalation study of FT576 will be presented at the conference.
Clinical data • P1 data • Combination therapy
|
IL15 (Interleukin 15)
|
cyclophosphamide • Darzalex (daratumumab) • fludarabine IV • FT576
4years
[VIRTUAL] FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma (ASH 2020)
There are multiple advantages in expanding treatment options beyond autologous primary T and NK cells, including the use of induced pluripotent stem cells (iPSC) to derive effector cells that can be uniformly manufactured at scale from renewable starting cellular material and where precision genetic engineering can be achieved at the clonal level which can be applied sequentially in order to build multiple specificities and functional modalities...Utilizing hnCD16, BCMA-CAR was tested in combination with anti-CD38 (daratumumab), anti-SLAMF7 (elotuzumab), or anti-CD19, showing synergistic increase in tumor targeting through various tumor associated antigens (TAAs)...Combination with other monoclonal antibodies displayed a similar response demonstrating the unique ability of FT576 to be directed to target multiple TAAs. Together, these studies demonstrate the versatility of FT576 as a highly effective multi-antigen targeting and cost-effective off-the-shelf BCMA-CAR iNK cell product and supports the rational for a first-of-kind Phase I Study as a monotherapy or in combination with therapeutic mAbs targeted to MM-associated surface antigens, driving a path towards a curative therapeutic in MM.
Combination therapy • IO biomarker
|
CD38 (CD38 Molecule)
|
Darzalex (daratumumab) • Empliciti (elotuzumab) • FT576